Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: Results from the Angina Prognosis Study In Stockholm (APSIS)

Atherosclerosis

Volumn 135, Issue 1, 1997, Pages 109-118

  Held, Claes ^a   Hjemdahl, Paul ^b   Rehnqvist, Nina ^c   Björkander, Inge ^a   Forslund, Lennart ^a   Brodin, Ulf ^d   Berglund, Lars ^d   Angelin, Bo ^e  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Ctr Metab Endocrinol Dept M   (Sweden)

Author keywords

Angina pectoris; Apolipoproteins; Lipoproteins; Prognosis

Indexed keywords

APOLIPOPROTEIN; LIPID; METOPROLOL; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

AGED; ANGINA PECTORIS; APOLIPOPROTEINS; CARDIOVASCULAR SYSTEM; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; METOPROLOL; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; VERAPAMIL;

EID: 0030778549     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00147-0     Document Type: Article

References (48)

1. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 74:1971;1-12.
2. Multiple Risk Factor Intervention Trial Research Group Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 248:1982;1465-1477.
3. The Lipid Research Clinics Program The lipid research clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
4. Gordon D.J., Knoke J., Probstfield J.L., Superko R., Tyroler H.A. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation. 74:1986;1217-1225.
5. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 63:1977;707-714.
6. Gordon T., Kannel W.B., Castelli W.P., Dawber T.R. Lipoproteins, cardiovascular disease and death. The Framingham study. Arch Intern Med. 141:1981;1128-1131.
7. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 11:1991;2-14.
8. Austin M.A. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol. 129:1989;249-259.
9. Bhatnagar D., Durrington P.N. Clinical value of apolipoprotein measurements. Ann Clin Biochem. 28:1991;427-437.
10. Avogaro P., Bittolo Bon G., Cazzolato G., Quinci G.B. Are apolipoproteins better discriminators than lipid for atherosclerosis? Lancet. 1:1979;910-913.
11. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381.
12. Wald N.J., Law M., Watt H.C.et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 343:1994;75-79.
13. Salonen J.T., Salonen R., Penttilä I.et al. Serum fatty acids, apolipoproteins, selenium and vitamin oxidants and the risk of death from coronary artery disease. Am J Cardiol. 56:1985;226-231.
14. Sigurdsson G., Baldursdottir A., Sigvaldason H., Agnarsson U., Thorgeirsson G., Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 69:1992;1251-1254.
15. Kaplan N.M. Cardiovascular risk reduction: the role of antihypertensive treatment. Am J Med. 90(Suppl 2A):1991;19S-20S.
16. Lithell H. Metabolic aspects of the treatment of hypertension. J Hypertens. 13(Suppl 2):1995;S77-S80.
17. Moderately elevated blood pressure. Report from SBU, the Swedish Council on Technology Assessment in Health Care. J Intern Med 1995;238(S737).
18. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.
19. Walldius G. Effect of verapamil on serum lipoproteins in patients with stable angina pectoris. Acta Med Scand Suppl. 681:1984;43-48.
20. McTavish D., Sorkin E.M. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs. 38(1):1989;19-76.
21. The Danish Study Group on Verapamil in Myocardial Infarction Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II-DAVIT II). Am J Cardiol. 66:1990;779-785.
22. Yusuf S., Held P., Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish verapamil infarction trial (DAVIT-II) and other recent studies. Am J Cardiol. 67:1991;1295-1297.
23. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation. 92:1995;1079-1082.
24. Rehnqvist N, Hjemdahl P, Billing E et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J 1996;17:76-81 (Erratum p. 783).
25. Hjemdahl P., Eriksson S.V., Held C., Rehnqvist N. Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol. 77:1996;6D-15D.
26. Held C., Hjemdahl P., Rehnqvist N.et al. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the angina prognosis study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med. 241:1997;59-69.
27. Lopes-Virella M.F., Stone P., Shelton E., Colwell J.A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 23:1977;882-884.
28. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
29. Parmar MKB, Machin D. Survival Analysis. A Practical Approach. Medical Research Council Cancer Trials Office, Cambridge, UK. Chichester: Wiley, 1995.
30. Billing E., Hjemdahl P., Rehnqvist N. Psychosocial variables in female versus male patients with stable angina pectoris and matched healthy controls. Eur Heart J. 18:1997;910-917.
31. O'Brien T., Ngyuen T.T., Hallaway B.J.et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol. 15:1995;228-231.
32. Ishakawa T., Fidge N., Thelle D.S., Forde O.H., Miller N.E. The Tromsö heart study: serum apolipoprotein A-I concentration in relation to future coronary heart disease. Eur J Clin Invest. 8:1978;179-182.
33. Lamarche B., Moorjani S., Lupien P.L.et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation. 94:1996;273-278.
34. Garfagnini A., Devoto G., Roselli P., Boggiano P., Venturini M. Relationship between HDL-cholesterol and apolipoprotein A-I and the severity of coronary artery disease. Eur Heart J. 16:1995;465-470.
35. Bolibar I., Thompson S.G., von Eckardstein A., Sandkamp M., Assman G. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent and comprehensive. Arterioscler Thromb Vasc Biol. 15:1995;1035-1042.
36. The MRFIT Research Group, Watkins L.O., Neaton J.D., Phillips A.N. High-density lipoprotein cholesterol and coronary heart disease incidence in black and white MRFIT usual care men. Am J Cardiol. 57:1986;538-545.
37. Assman G., Schuldte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 70:1992;733-737.
38. Patsch J. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 110:1994;S23-S26.
39. Durrington P.N., Ishola M., Hunt L., Arrol S., Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset of ischemic heart disease. Lancet. 1:1988;1070-1073.
40. Genest J.J., McNamara J.R., Ordovas J.M.et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 19:1992;792-802.
41. Kannel W.B. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J. 110:1985;1100-1107.
42. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250 and 310-318.
43. Hamsten A., Walldius G., Dahlén G., Johansson B., De Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis. 59:1986;223-235.
44. Al-Muhtaseb N., Hayat N., Al-Khafaji M. Lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis. 77:1989;131-138.
45. Fager G., Wiklund O., Olofsson S.-O., Wilhelmsen L., Bondjers G. Multivariate analyses of serum apolipoproteins and risk factors in relation to acute myocardial infarction. Arteriosclerosis. 1:1981;273-279.
46. Kaplan J.R., Manuck S.B., Adams M.R., Clarkson T.B. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J. 8:1987;928-944.
47. Henry P.D. Atherosclerosis, calcium and calcium antagonists. Circulation. 72:1985;546-549.
48. Bondjers G. Anti-atherosclerotic effects of beta-blockers. Eur Heart J. 15(C):1994;8-15.